Skip to main content
TipRanks
Go Ultimate75% OFF

Voyageur Pharmaceuticals (VYYRF) AI Stock Analysis

2 Followers
VYYRF

Voyageur Pharmaceuticals

(Other OTC:VYYRF)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Low Financial LeverageVery low leverage reduces immediate financial risk and preserves flexibility for Voyageur to fund project development or absorb operating volatility. The limited debt burden also avoids substantial interest pressure while the company works toward commercial scale and improved profitability.
Negative Factors
Persistent UnprofitabilityDeep losses and negative gross profit show that the current revenue base is not covering the cost structure. This weak profitability can erode the equity base over time and indicates that meaningful commercial scaling or expense improvement is still required before earnings become durable.

Voyageur Pharmaceuticals (VYYRF) vs. SPDR S&P 500 ETF (SPY)

-200%0%200%400%600%800%1000%VYYRF-11.00%SPY+11.99%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$20.25M
Dividend Yield
―
Average Volume (3M)
49.62K
Price to Earnings (P/E)
-6.8
Beta (1Y)
-25.47
Revenue Growth
357.24%
EPS Growth
14.08%
Country
US
Employees
49
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - Specialty & Generic

Voyageur Pharmaceuticals Business Overview & Revenue Model

Company Description

Voyageur Pharmaceuticals Ltd. specializes in the creation of mineral-based active pharmaceutical ingredients (APIs). The company aims to produce radiocontrast agents utilizing barium and iodine, along with pharmaceutical products derived from bromine...

Voyageur Pharmaceuticals Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

VYYRF against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
TSE:AVCNTSE:AVCN58NeutralCAD 12.09M-3.98-65.40%―-3.32%-34.15%
TSE:LABSTSE:LABS57NeutralCAD 27.77M-9.23-7.66%―-9.31%66.84%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
TSE:ROMJTSE:ROMJ48NeutralCAD 23.99M-5.33-10.97%―16.91%-244.25%
TSE:INNOTSE:INNO41NeutralCAD 8.28M-6.18-19.37%―-19.20%42.54%
TSE:PCLOTSE:PCLO39UnderperformCAD 8.41M-2.4128.59%―0.90%57.73%

* Healthcare Sector Average

Performance Comparison

0%200%400%600%800%VYYRFTSE:LABSTSE:PCLOTSE:ROMJTSE:AVCNTSE:INNODec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
VYYRF and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
VYYRFVoyageur Pharmaceuticals Ltd.0.09-0.01-11.00%
TSE:LABSMedipharm Labs (Otc)0.06-0.01-7.69%
TSE:PCLOPharmacielo0.040.000.00%
TSE:ROMJRubicon Organics 0.35-0.10-21.11%
TSE:AVCNAvicanna Inc0.09-0.15-63.33%
TSE:INNOInnocan Pharma Corporation1.84-13.55-88.04%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.